van Heest J A, Bokma J A, van Oudheusden L J, Stricker B H
Erasmus Universiteit, Huisartsinstituut, Rotterdam.
Ned Tijdschr Geneeskd. 1994 Oct 29;138(44):2204-7.
The Netherlands Centre for Monitoring of Adverse Reactions to Drugs received two reports of adrenal suppression, attributed to inhaled budesonide. In the first patient, a 7-year-old girl, there were growth retardation, centripetal weight gain and a Cushingoid moonface with unmeasurable serum levels of cortisol after long-term treatment with 600, and later 1000 micrograms daily. In the second patient, an 8-year-old boy, there was malaise with onset a few months after start of treatment with 400 micrograms budesonide daily. There was a lowered serum level of cortisol which returned to normal after discontinuation of budesonide. Although inhaled corticosteroids cause systemic adverse effects less frequently than orally administered corticosteroids, such effects may occur occasionally.
荷兰药物不良反应监测中心收到两份肾上腺抑制的报告，归因于吸入布地奈德。首例患者为一名7岁女童，长期每日使用600微克、后增至1000微克布地奈德治疗后，出现生长发育迟缓、向心性体重增加及库欣样满月脸，血清皮质醇水平无法测定。第二例患者为一名8岁男童，每日使用400微克布地奈德治疗数月后出现不适。血清皮质醇水平降低，停用布地奈德后恢复正常。尽管吸入性糖皮质激素引起全身不良反应的频率低于口服糖皮质激素，但此类效应仍可能偶尔发生。
